Corporate
News release
Top
TOKYO, JAPAN - January 7, 2019 - Terumo Corporation (TSE: 4543) today announced that it completed its acquisition of Essen Technology (Beijing) Co., Ltd., a Chinese medical device company, on December 29, 2018. Under the terms of the agreement, Terumo will pay 879 million Chinese Yuan upfront and milestone payment based on the future performance. It will be funded through cash on hand and Terumo does not regard the impact of the acquisition on Terumo's business performance of the fiscal year ending March 31, 2019 as significant.
Essen Technology is a specialized enterprise of drug-eluting stents (DES). Terumo has grown rapidly in China selling interventional products, such as guidewires and balloon catheters. However, it has not yet offered coronary stents in that market.
Terumo has expanded its DES sales coverage to include Japan, Europe, Asia, and Latin America, for a total of over 40 countries. This acquisition will add China, which is expected to become the biggest market in a few years, to Terumo's geographical DES portfolio. In China, there are more than 750,000 percutaneous coronary intervention cases, and they are projected to increase by over 10% annually.
Entering the Chinese market, where the importance of domestic products is increasing, with a domestically manufactured DES helps Terumo to expand its interventional systems business.
Notes: Terumo's regional strategy for China
Terumo has pursued its strategy in each region appropriately to the local market and its position there, while globalizing uniformly under business-led management. Terumo has moved to localize its business in China, entering into alliances with local players in selected fields, including peritoneal dialysis, renal denervation catheters and neuroendovascular therapy.
About Terumo
Terumo (TSE: 4543) is a global leader in medical technology and has been committed to “Contributing to Society through Healthcare” for 100 years. Based in Tokyo and operating globally, Terumo employs more than 30,000 associates worldwide to provide innovative medical solutions in more than 160 countries and regions. The company started as a Japanese thermometer manufacturer, and has been supporting healthcare ever since. Now, its extensive business portfolio ranges from vascular intervention and cardio-surgical solutions, blood transfusion and cell therapy technology, to medical products essential for daily clinical practice such as transfusion systems, diabetes care, and peritoneal dialysis treatments. Terumo will further strive to be of value to patients, medical professionals, and society at large.